Alphamab Oncology (HKG: 9966), a biopharmaceutical company based in China, has entered into a licensing agreement with fellow Chinese firm CSPC Pharmaceutical Group Ltd (HKG: 1093). The deal grants CSPC exclusive license and sub-license rights to Alphamab’s JSKN003 in mainland China for development, sales, and commercialization related to oncology indications. As a result, CSPC becomes the sole Marketing Authorization Holder (MAH) for JSKN003 in mainland China, taking on the clinical development costs while Alphamab retains manufacturing rights.
JSKN003 is a HER2 targeted antibody-drug conjugate (ADC) that utilizes a click reaction, which is considered to offer improved serum stability over conjugates based on the maleimide-Michael reaction. Early clinical data suggest that JSKN003 has good tolerability and safety, demonstrating significant efficacy in various advanced solid tumors that have been previously treated with multiple lines of systemic therapy.
Under the terms of the agreement, CSPC will pay Alphamab a total of RMB 3.08 billion, which includes an upfront payment of RMB 400 million and a development milestone payment of RMB 300 million, along with double-digit net sales royalties.- Flcube.com
